[12] Patent
[11] Patent No.:GC0011528  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2020                77/2020  		 Number of the Decision to Grant the Patent:2020/176286
Date of the Decision to Grant the Patent:09/Dec/2020

[21] Application No.:GC 2012-21503

[22] Filing Date:13/6/2012

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
17/6/2011
 61/498,110

[72] Inventors:1- Carl BROOKS،2- Mui CHEUNG،3- Hilary Schenck EIDAM،4- Krista B. GOODMAN،5- Marlys HAMMOND،6- Mark A. HILFIKER،7- Tram H. HOANG،8- Jaclyn R. PATTERSON،9- Patrick STOY،10- Guosen YE

[73] Owner: GLAXOSMITHKLINE LLC, One Franklin Plaza, 200 North 16th Street, Philadelphia, Pennsylvania 19102, U.S.A, Philadelphia, USA

[74] Agent: Saba & Co. T.M.P

  

 

   

[51]IPC:
C07D263/52, C07D498/00, C07D419/14

[56] Cited Documents:

-US 20010130400 A1 (BURY et al.) 2 June 2011
-US 20090062345 A1 (VASUDEVAN et al.) 5 March 2009
-EVERAERTS ET AL.: 'The vanilloid transient receptor potential channel TRPV4: From structure to disease in Progress.’ BIOPHYSICS AND MOLECULAR BIOLOGY vol. 103, 2010, pages 2 - 17, XP027181425
-US 20100216821 A1 (Barton et al.) 26 August 2010
-US 20090042897 A1 (Bentley et al.) 12 February 2009  
Examiner: PH. Abrar AlSaleem

[54] TRPV4 ANTAGONISTS
[57] Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
No. of claims: 10


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.